Therapy with iloprost in patients with severe Raynaud's phenomenon secondary to scleroderma

Revmatologiia

Volumn 14, Issue 1, 2006, Pages 33-36

  Lambova, S ^b   Kuzmanova, St ^a   Stoianova, L ^b   Rusafov, P ^b   Penev, D ^b  

^a University Clinic of Rheumatology   (Bulgaria)

^b NONE

Author keywords

Iloprost; Raynaud's phenomenon

Indexed keywords

ILOPROST;

ARTICLE; DISEASE SEVERITY; DOWN REGULATION; DRUG EFFICACY; DRUG SAFETY; ENDOTHELIUM CELL; FOLLOW UP; HUMAN; PAIN; PHAGOCYTE; PROTEIN EXPRESSION; RAYNAUD PHENOMENON; SCLERODERMA; THROMBOCYTE AGGREGATION; ULCER; UNSPECIFIED SIDE EFFECT; WOUND HEALING;

EID: 33745726465     PISSN: 13100505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Bettoni, L. et al. Systemic sclerosis therapy with iloprost: a prospective observational study of 30 patients treated for a median of 3 years. - Clin. Rheumatol., 21, 2002, No 3, 244-250.
2. Della Bella, S. et al. Novel mode of action of iloprost: in vitro down-regulation of endothelial cell adhesion molecules. - Prostaglandins other lipid mediat., 65, 2001, No 2-3, 73-83.
3. Filaci, G. et al. Cyclosporin A and iloprost treatment of systemic sclerosis: clinical results and interleukin-6 serum changes after 12 months of therapy. - Rheumatology, 38, 1999, No 10, 992-996.
4. Herrick, A. L. Treatment of Raynaud's phenomenon: new insights and developments. - Curr. Rheumatol. Rep., 5, 2003, No 2, 168-174.
5. Herric, A. L. et M. M. Cerrinic. The emerging problem of oxidative stress and the role of antioxidants in systemic sclerosis. - Clin. Exp. Rheumatol., 19, 2001, No 1, 4-8.
6. Kahaleh, B. O. Meyer et R. Scorza. Assessment of vascular involvement. - Clin. Exp. Rhematol., 21, 2003, Suppl. 29, 9-14.
7. rd edition 1215-1235.
8. Ling, S. M. et F. M. Wigley. Raynaud's phenomenon in older adults: diagnostic considerations and management. - Drugs Aging, 15, 1999, No 3, 183-195.
9. Merkel, P. A. et al. Measuring disease activity and functional status in patients with scleroderma and Raynaud's phenomenon. - Arthritis Rheum., 46, 2002, No 9, 2410-2420.
10. Mittag, M. et U. F. Beckheinrich. Systemic sclerosis-related Raynaud's phenomenon: effects of iloprost infusion therapy on serum cytokine, growth factor and soluble adhesion molecule levels. - Acta Derm. Venereol., 81, 2001, No 4, 294-297.
11. th ed., Lippincott, Williams & Wilkins, 2000, 82-87.
12. Rajagopalan, S. et al. Increased asymmetric dimethylarginine and endotheline 1 levels in secondary Raynaud's phenomenon. - Arthritis Rheum., 48, 2003, No 7, 1992-2000.
13. Scorza, R. et al. Effects of long-term cyclic iloprost therapy in systemic sclerosis with Raynaud's phenomenon. A randomized, controlled study. - Clin. Exp. Rheumatol. 19, 2001, No 5, 503-508.
14. Strallon, R. et al. Iloprost suppresses connective tissue growth factor production in fibroblasts and in the skin of scleroderma patients. - J. Clin. Invest., 108, 2001, No 2, 241-250.
15. Wigley, F. M. et al. Intravenous Iloprost in patients with Raynaud's phenomenon secondary to systemic sclerosis. - Ann. Int. Med., 120, 1994, No 3, 199-206.